Article
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Clinical lung cancer - 1 May 2023
Iams Wade T, Balbach Meridith L, Phillips Sharon, Sacher Adrian, Bestvina Christine, Velcheti Vamsidhar, Wang Xiao, Marmarelis Melina E, Sethakorn Nan, Leal Ticiana, Sackstein Paul E, Kim Chul, Robinson Md Andrew, Mehta Kathan, Hsu Robert, Nieva Jorge, Patil Tejas, Camidge D Ross
Abstract excerpt
BACKGROUND: On May 28, 2021, the United States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for second-line or later treatment of patients with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC). This was the first FDA-approved targeted therapy for this patient population. Due to a paucity of real world data describing clinical outcomes in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.